Table 1 Summary of included studies in systematic review
From: Atrial fibrillation in cancer survivors – a systematic review and meta-analysis
Study | Study Design | Cancer Type | Staging | Age (SD) | Cancer Patients (n) | Treatment | Median Follow-up (years ± SD) | AF Definition | AF Screening Method | Male (%) | HTN (%) | DM (%) | IHD (%) | CCF (%) | Previous stroke (%) | AF Rate (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rao et al. (2012)(25) | Retrospective cohort | Oesophageal | NA | 68 | 997 | Chemotherapy (5-FU, CP, capecitabine, epirubicin), Oesophagectomy | NA | NA | 12-lead ECG | 71.1 | 23.7 | 7.9 | 11.1 | NA | NA | 21 |
Hesselink et al. (2015)(23) | Retrospective cohort | Thyroid | 82.4% Tx – T3 17.6% T4 65.8% Nx-N0 34.2% N1 90.7% Mx-M0 9.3% M1 | 48.6 (14) | 518 | Thyroidectomy, Radioiodine Ablation, Thyroid Hormone Suppression Therapy | 8.7 | NA | ECG or diagnosed from cardiologist | 25.3 | 17 | 4.2 | NA | 0.2 | NA | 6.8 |
O’Neal et al. (2015)(24) | Cross-sectional | Various | NA | 70 (8.6) | 2,248 | NA | NA | NA | Scheduled ECG or self-reported history of physician diagnosis | 59 | 55 | 20 | NA | NA | NA | 11 |
Chalazan et al. (2016)(29) | Retrospective cohort | Breast | NA | 58.9 (12.8) | 2,124 | Chemotherapy (tyrosine kinase inhibitors, alkylating agents, monoclonal antibodies, antimetabolites, mitotic inhibitors, hormone modifiers, topoisomerase inhibitors, antineoplastic antibiotics), Radiotherapy | NA | Validated algorithm | NA | NA | NA | NA | NA | NA | NA | 4 |
Sorigue et al. (2018)(27) | Retrospective cohort | Non-Hodgkin lymphoma | 34% I – II 66% III – IV | 61 | 724 | Chemotherapy | 5.3 | NA | 12-lead ECG | 52 | 32 | 16 | NA | NA | NA | 5.5 |
Abdel-Qadir et al. (2019) (16) | Population-based, retrospective, matched cohort study | Breast | 44.3% I 38.7% II 13.4% III 3.6% Unknown | 60 (13) | 68,113 | Chemotherapy (anthracycline, trastuzumab, other), Radiotherapy, Mastectomy | 5.7 (2.9) | Validated algorithm | NA | 0 | 43.4 | 15.9 | 5.5 | 2.1 | 0.4 | 4.6 |
D’Souza et al. (2019)(18) | Retrospective cohort | Breast | NA | 62 | 74,155 | NA | 3 | Hospitalization with discharged diagnosis of AF | NA | 0 | 19.1 | 4.4 | 3.7 | 1.2 | NA | 1.3 |
Jacobs et al. (2019)(28) | Retrospective cohort | Breast | NA | 57.6 (13.4) | 1,338 | Radiotherapy | 10 | NA | ECG | 0.9 | NA | NA | NA | NA | NA | 5.2 |
Hayashi et al. (2019)(19) | Retrospective cohort | Oesophageal | cT1N0M0 stage IA | 66.5 | 80 | Chemotherapy (5-FU, CP, nedaplatin), Radiotherapy | 6.1 | NA | NA | 88.8 | 45 | 12.5 | NA | NA | NA | 1.25 |
Jakobsen et al. (2019)(20) | Retrospective registry-based cohort | Various | NA | 67 (13.3) | 316,040 | NA | 12 | ICD-10 codes | NA | 48.5 | 35.2 | NA | 5.5 | 2 | 6.2 | 5.7 |
Mery et al. (2020)(21) | Retrospective cohort | Breast | 0.70% O 47.9% I 33.1% II 11.0% III 2.20% IV | 62.5 | 682 | Chemotherapy (5-FU, epirubicin, cyclophosphamide, docetaxel, DXR, PTX, CB), Radiotherapy, Surgery, Endocrine Therapy, Trastuzumab | 5 | NA | NA | 0.9 | 73.8 | 17.4 | NA | NA | NA | 0.7 |
Li et al. (2021)(26) | Cross-sectional | Breast, Lung, Colorectal, Gastric, Thyroid | NA | 69.12 (9.89) | 35,861 | NA | NA | NA | 12-lead ECG or in 24-hour single-lead ECG recording or Holter | 51.6 | 21.9 | 29.2 | 6.5 | 1 | NA | 2.9 |
Parahuleva et al. (2021)(22) | Prospective case-control | Endometrial | NA | 63.34 (7.03) | 310 | Chemotherapy (PTX, CB, DXR, liposomal DXR, CP, docetaxel), Hormone Therapy, Surgery | 2.5 (0.5) | NA | 12-lead ECG, hospital discharge diagnosis, death certificate | 0 | NA | NA | NA | NA | NA | 11.7 |
Yun et al. (2021)(9) | Retrospective cohort | Various | NA | 57.51 (12.48) | 816,811 | NA | 4.5 | ICD-10 codes | NA | 46.9 | 39.7 | 16.5 | NA | NA | NA | 3.1 |
Guha et al. (2022)(8) | Retrospective cohort | Breast | 35.5% I 32.6% II 17.1% III 14.8% IV | 78 | 85,423 | Chemotherapy (anthracyclines, HER2-inhibitors, cyclophosphamide, taxanes, platinum-based agents), Surgery, Radiotherapy, Hormone Therapy | 1 | ICD-9-CM codes | NA | 0 | 74.6 | 37.3 | 44.8 | 31.2 | 14.3 | 3.5 |
Beukema et al. (2022)(17) | Prospective cross-sectional | Oesophageal | NA | 67.8 (NA) | 40 | Chemotherapy (CB, PTX), Radiotherapy, Surgery | 7.3 | NA | NA | NA | 20 | 35 | 10 | 0 | NA | 30 |